A Legal AI Story With Evidence Attached
Artificial intelligence has produced no shortage of opening statements. CS Disco, Inc. (NYSE: LAW) is beginning to assemble something more persuasive: evidence. The Austin-based litigation technology company reported third-quarter 2026 revenue of $45.3 million, an 11%…
A Funded Biotech With a Date Worth Watching
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) is approaching a consequential clinical milestone with something that makes the occasion considerably more interesting: enough financial breathing room to focus on the science. The company’s November…
AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst
Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…
Drilling automation, lower operating costs and stronger refining margins give investors reasons to look beyond the next oil-price headline.
October 7, 2026
Inflation has an unfortunate habit of returning just as investors begin discussing it in the past tense. But for energy…
